COVID-19-associated myelitis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (44 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{SI}} | ||
{{CMG}}; {{AE}} {{sali}} [[User:Tayebah Chaudhry|Tayebah Chaudhry]][mailto:dr.thch@yahoo.com] | {{CMG}}; {{AE}} {{sali}} [[User:Tayebah Chaudhry|Tayebah Chaudhry]][mailto:dr.thch@yahoo.com], {{Fs}} | ||
{{SK}} | {{SK}} | ||
==Overview== | ==Overview== | ||
In the current [[pandemic]] state, [[COVID-19]] should be considered as a differential diagnosis in a patient presenting with acute [[myelitis]]. | In the current [[pandemic]] state, [[COVID-19]] should be considered as a differential diagnosis in a patient presenting with acute [[myelitis]]. Acute Transverse Myelitis is a neurological condition characterized by inflammation and injury of the [[spinal cord]]. In a confirmed or newly diagnosed patient of COVID-19, it is thought to be either a direct consequence of viral infection or a sequalae of [[autoimmune]]-mediated response. COVID-19-associated myelitis is diagnosed based on the hallmark symptoms of acute myelitis and confirmed with changes on spinal MRI, after ruling out other possible etiologies of myelitis. The symptoms show marked improvement after treatment with [[steroids]] and [[plasma exchange]]. | ||
==Historical Perspective== | ==Historical Perspective== | ||
| Line 13: | Line 13: | ||
* First case of acute [[myelitis]] as a [[COVID-19]] complication was reported in February 2020 in Wuhan by Kang Zhao et al, in a 66 year old male patient. <ref name="urlwww.medrxiv.org">{{cite web |url=https://www.medrxiv.org/content/10.1101/2020.03.16.20035105v1.full.pdf |title=www.medrxiv.org |format= |work= |accessdate=}}</ref> | * First case of acute [[myelitis]] as a [[COVID-19]] complication was reported in February 2020 in Wuhan by Kang Zhao et al, in a 66 year old male patient. <ref name="urlwww.medrxiv.org">{{cite web |url=https://www.medrxiv.org/content/10.1101/2020.03.16.20035105v1.full.pdf |title=www.medrxiv.org |format= |work= |accessdate=}}</ref> | ||
* The second case was reported in Boston by Sarma et al in a 28 year old female patient who developed acute myelitis 7 days after symptoms of [[upper respiratory tract infection]]. <ref name="urlA Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection">{{cite web |url=https://escholarship.org/uc/item/0mj588gb |title=A Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection |format= |work= |accessdate=}}</ref> | * The second case was reported in Boston by Sarma et al in a 28 year old female patient who developed acute myelitis 7 days after symptoms of [[upper respiratory tract infection]]. <ref name="urlA Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection">{{cite web |url=https://escholarship.org/uc/item/0mj588gb |title=A Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection |format= |work= |accessdate=}}</ref> | ||
*As of now, few case reports have been published in literature showing an association of COVID-19 with acute myelitis as a neurological complication. | *As of now, only few case reports have been published in literature showing an association of COVID-19 with acute myelitis as a neurological complication. | ||
==Classification== | ==Classification== | ||
* There is no established system for the classification of | * There is no established system for the classification of COVID-19-associated myelitis. | ||
==Pathophysiology== | ==Pathophysiology== | ||
| Line 25: | Line 25: | ||
*This evidence is based on the previous extensive [[SARS-CoV]] structural analyses that showed interactions between the [[SARS-CoV]] [[virus]] and [[ACE2 receptor]]s and because of the marked sequence similarities between [[Covid-19]] and the [[SARS-CoV]] [[virus]] it is hypothesized that [[COVID 19]] [[virus]] [[pathogenesis]] is comparable. | *This evidence is based on the previous extensive [[SARS-CoV]] structural analyses that showed interactions between the [[SARS-CoV]] [[virus]] and [[ACE2 receptor]]s and because of the marked sequence similarities between [[Covid-19]] and the [[SARS-CoV]] [[virus]] it is hypothesized that [[COVID 19]] [[virus]] [[pathogenesis]] is comparable. | ||
*The [[ACE2 receptor]]s are expressed on [[alveolar epithelial cell]]s, [[intestinal enterocytes]] and [[arterial]] and [[venous]] [[endothelial cell]]s. | *The [[ACE2 receptor]]s are expressed on [[alveolar epithelial cell]]s, [[intestinal enterocytes]] and [[arterial]] and [[venous]] [[endothelial cell]]s. | ||
* | *In the brain, only the vascular cells expressed ACE2 cell receptors, not the neurons; yet attachment of the virus to the vascular endothelium this could be a potential mechanism for dissemination of the virus into the brain by the blood circulation<ref name="pmid32312872">{{cite journal| author=Manji H, Carr AS, Brownlee WJ, Lunn MP| title=Neurology in the time of COVID-19. | journal=J Neurol Neurosurg Psychiatry | year= 2020 | volume= 91 | issue= 6 | pages= 568-570 | pmid=32312872 | doi=10.1136/jnnp-2020-323414 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32312872 }} </ref>. | ||
*It is also hypothesized that the virus can disseminate into the nervous system through the olfactory bulb in which sensory neurons connect the nasal cavity to the central nervous system by the axons, which terminate in the olfactory bulb and passes through the cribriform plate<ref name="pmid31996437">{{cite journal| author=Wan Y, Shang J, Graham R, Baric RS, Li F| title=Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. | journal=J Virol | year= 2020 | volume= 94 | issue= 7 | pages= | pmid=31996437 | doi=10.1128/JVI.00127-20 | pmc=7081895 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31996437 }} </ref>. | *It is also hypothesized that the virus can disseminate into the nervous system through the olfactory bulb in which sensory neurons connect the nasal cavity to the central nervous system by the axons, which terminate in the olfactory bulb and passes through the cribriform plate<ref name="pmid31996437">{{cite journal| author=Wan Y, Shang J, Graham R, Baric RS, Li F| title=Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. | journal=J Virol | year= 2020 | volume= 94 | issue= 7 | pages= | pmid=31996437 | doi=10.1128/JVI.00127-20 | pmc=7081895 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31996437 }} </ref>. | ||
*Early‐phase [[COVID‐19]]‐affected patients | *Early‐phase [[COVID‐19]]‐affected patients may exhibit loss of smell and taste as a result of this <ref name="pmid32266761">{{cite journal| author=Baig AM| title=Neurological manifestations in COVID-19 caused by SARS-CoV-2. | journal=CNS Neurosci Ther | year= 2020 | volume= 26 | issue= 5 | pages= 499-501 | pmid=32266761 | doi=10.1111/cns.13372 | pmc=7163592 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32266761 }} </ref>. | ||
* | *In advanced stages of the disease the [[neurological]] [[signs and symptom]]s observed with [[COVID‐19]] could also be due to the effects of [[hypoxia]], [[respiratory]], and [[metabolic acidosis]]<ref name="Pastor BandeiraMachado Schlindwein2020">{{cite journal|last1=Pastor Bandeira|first1=Isabelle|last2=Machado Schlindwein|first2=Marco Antônio|last3=Breis|first3=Leticia Caroline|last4=Schatzmann Peron|first4=Jean Pierre|last5=Magno Gonçalves|first5=Marcus Vinicius|year=2020|doi=10.20944/preprints202004.0304.v1}}</ref>. | ||
==Causes== | ==Causes== | ||
Apart from [[COVID-19]] other causes of viral myelitis include<ref name="pmid26209588">{{cite journal| author=Pekcevik Y, Mitchell CH, Mealy MA, Orman G, Lee IH, Newsome SD | display-authors=etal| title=Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging. | journal=Mult Scler | year= 2016 | volume= 22 | issue= 3 | pages= 302-11 | pmid=26209588 | doi=10.1177/1352458515591069 | pmc=4797654 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26209588 }} </ref>: | |||
*[[Herpes viruse]]s, including the one that causes [[shingles]] and [[chickenpox]] ([[zoster]]) | *[[Herpes viruse]]s, including the one that causes [[shingles]] and [[chickenpox]] ([[zoster]]) | ||
| Line 45: | Line 45: | ||
*[[Hepatitis B]] | *[[Hepatitis B]] | ||
*[[Mumps]], [[measles]] and [[rubella]] | *[[Mumps]], [[measles]] and [[rubella]] | ||
Other causes of myelitis are: | |||
*[[Bacterial myelitis]] | |||
*[[Fungal myelitis]] | |||
*[[Parasitic myelitis]] | |||
*[[Multiple Sclerosis]] | |||
*[[Transverse Myelitis]] | |||
*[[Autoimmune]] disorders like [[SLE]] and [[Sjogren’s Syndrome]] | |||
*[[Sarcoidosis]] | |||
*[[Vaccinations]] | |||
==Differentiating COVID-19-associated myelitis from other Diseases== | ==Differentiating COVID-19-associated myelitis from other Diseases== | ||
* | *For further information about the differential diagnosis, [[COVID-19-associated myelitis differential diagnosis|click here]]. | ||
*To view the differential diagnosis of COVID-19, [[COVID-19 differential diagnosis|click here]]. | |||
* | |||
To view the differential diagnosis of COVID-19, [[COVID-19 differential diagnosis|click here]]. | |||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
* As of now, the incidence of acute myelitis associated with Covid-19 infection in unknown. <ref name="AlKetbiAlNuaimi2020">{{cite journal|last1=AlKetbi|first1=Reem|last2=AlNuaimi|first2=Dana|last3=AlMulla|first3=Muna|last4=AlTalai|first4=Nouf|last5=Samir|first5=Mohammed|last6=Kumar|first6=Navin|title=Acute Myelitis as a Neurological Complication ofCovid-19:A Case Report and MRI Findings|journal=Radiology Case Reports|year=2020|issn=19300433|doi=10.1016/j.radcr.2020.06.001}}</ref><ref name="pmid32458198">{{cite journal| author=Munz M, Wessendorf S, Koretsis G, Tewald F, Baegi R, Krämer S | display-authors=etal| title=Acute transverse myelitis after COVID-19 pneumonia. | journal=J Neurol | year= 2020 | volume= | issue= | pages= | pmid=32458198 | doi=10.1007/s00415-020-09934-w | pmc=7250275 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32458198 }} </ref> | * As of now, the incidence of acute myelitis associated with Covid-19 infection in unknown. <ref name="AlKetbiAlNuaimi2020">{{cite journal|last1=AlKetbi|first1=Reem|last2=AlNuaimi|first2=Dana|last3=AlMulla|first3=Muna|last4=AlTalai|first4=Nouf|last5=Samir|first5=Mohammed|last6=Kumar|first6=Navin|title=Acute Myelitis as a Neurological Complication ofCovid-19:A Case Report and MRI Findings|journal=Radiology Case Reports|year=2020|issn=19300433|doi=10.1016/j.radcr.2020.06.001}}</ref><ref name="pmid32458198">{{cite journal| author=Munz M, Wessendorf S, Koretsis G, Tewald F, Baegi R, Krämer S | display-authors=etal| title=Acute transverse myelitis after COVID-19 pneumonia. | journal=J Neurol | year= 2020 | volume= | issue= | pages= | pmid=32458198 | doi=10.1007/s00415-020-09934-w | pmc=7250275 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32458198 }} </ref> | ||
*To view epidemiology and demographics for COVID-19, [[COVID-19 epidemiology and demographics|click here]].<br /> | |||
==Risk Factors== | ==Risk Factors== | ||
* There are no established risk factors for COVID-19-associated myelitis. However, since | * There are no established risk factors for COVID-19-associated myelitis. However, since this condition is a direct consequence of infection by the novel coronavirus, risk factors for [[COVID-19]] should be considered. | ||
*To view the risk factors of COVID-19, [[COVID-19 risk factors|click here]]. | |||
==Screening== | ==Screening== | ||
| Line 85: | Line 78: | ||
==Natural History, Complications, and Prognosis== | ==Natural History, Complications, and Prognosis== | ||
'''Natural History''' | |||
* Myelitis associated with COVID-19 is an acute condition. The first case of COVID-19 associated myelitis developed the symptoms 5 days after the onset of fever. <ref name="urlwww.medrxiv.org">{{cite web |url=https://www.medrxiv.org/content/10.1101/2020.03.16.20035105v1.full.pdf |title=www.medrxiv.org |format= |work= |accessdate=}}</ref> | |||
*The second case developed symptoms of myelitis 7 days after the upper respiratory symptoms. <ref name="urlA Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection">{{cite web |url=https://escholarship.org/uc/item/0mj588gb |title=A Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection |format= |work= |accessdate=}}</ref> | |||
'''Complications''' | |||
*Lack of prompt recognition and management may result in lasting neurological complications (such as residual loss of sensation in lower extremities) after novel corona virus infection. <ref name="urlA Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection">{{cite web |url=https://escholarship.org/uc/item/0mj588gb |title=A Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection |format= |work= |accessdate=}}</ref> | |||
'''Prognosis''' | |||
*Exact prognosis of COVID-19-associated myelitis is not known. | *Exact prognosis of COVID-19-associated myelitis is not known. | ||
*Marked improvement in symptoms is seen with steroids and plasma exchange. | *Marked improvement in symptoms is seen with steroids and plasma exchange. | ||
==Diagnosis== | ==Diagnosis== | ||
| Line 96: | Line 97: | ||
===History and Symptoms=== | ===History and Symptoms=== | ||
'''Common symptoms''' | |||
*[[Paraplegia]] <ref name="AlKetbiAlNuaimi2020">{{cite journal|last1=AlKetbi|first1=Reem|last2=AlNuaimi|first2=Dana|last3=AlMulla|first3=Muna|last4=AlTalai|first4=Nouf|last5=Samir|first5=Mohammed|last6=Kumar|first6=Navin|title=Acute Myelitis as a Neurological Complication ofCovid-19:A Case Report and MRI Findings|journal=Radiology Case Reports|year=2020|issn=19300433|doi=10.1016/j.radcr.2020.06.001}}</ref> | *[[Paraplegia]] <ref name="AlKetbiAlNuaimi2020">{{cite journal|last1=AlKetbi|first1=Reem|last2=AlNuaimi|first2=Dana|last3=AlMulla|first3=Muna|last4=AlTalai|first4=Nouf|last5=Samir|first5=Mohammed|last6=Kumar|first6=Navin|title=Acute Myelitis as a Neurological Complication ofCovid-19:A Case Report and MRI Findings|journal=Radiology Case Reports|year=2020|issn=19300433|doi=10.1016/j.radcr.2020.06.001}}</ref> | ||
| Line 102: | Line 103: | ||
* Lower back pain <ref name="urlA Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection">{{cite web |url=https://escholarship.org/uc/item/0mj588gb |title=A Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection |format= |work= |accessdate=}}</ref> | * Lower back pain <ref name="urlA Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection">{{cite web |url=https://escholarship.org/uc/item/0mj588gb |title=A Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection |format= |work= |accessdate=}}</ref> | ||
* Weakness in lower extremities <ref name="AlKetbiAlNuaimi2020">{{cite journal|last1=AlKetbi|first1=Reem|last2=AlNuaimi|first2=Dana|last3=AlMulla|first3=Muna|last4=AlTalai|first4=Nouf|last5=Samir|first5=Mohammed|last6=Kumar|first6=Navin|title=Acute Myelitis as a Neurological Complication ofCovid-19:A Case Report and MRI Findings|journal=Radiology Case Reports|year=2020|issn=19300433|doi=10.1016/j.radcr.2020.06.001}}</ref> | * Weakness in lower extremities <ref name="AlKetbiAlNuaimi2020">{{cite journal|last1=AlKetbi|first1=Reem|last2=AlNuaimi|first2=Dana|last3=AlMulla|first3=Muna|last4=AlTalai|first4=Nouf|last5=Samir|first5=Mohammed|last6=Kumar|first6=Navin|title=Acute Myelitis as a Neurological Complication ofCovid-19:A Case Report and MRI Findings|journal=Radiology Case Reports|year=2020|issn=19300433|doi=10.1016/j.radcr.2020.06.001}}</ref> | ||
'''Less common symptoms''' | |||
* [[Paresthesias]] in lower extremities with possible ascension to upper extremities <ref name="urlA Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection">{{cite web |url=https://escholarship.org/uc/item/0mj588gb |title=A Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection |format= |work= |accessdate=}}</ref> | * [[Paresthesias]] in lower extremities with possible ascension to upper extremities <ref name="urlA Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection">{{cite web |url=https://escholarship.org/uc/item/0mj588gb |title=A Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection |format= |work= |accessdate=}}</ref> | ||
* [[Numbness]] in lower extremities with possible ascension to upper extremities<ref name="urlA Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection">{{cite web |url=https://escholarship.org/uc/item/0mj588gb |title=A Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection |format= |work= |accessdate=}}</ref> | * [[Numbness]] in lower extremities with possible ascension to upper extremities<ref name="urlA Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection">{{cite web |url=https://escholarship.org/uc/item/0mj588gb |title=A Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection |format= |work= |accessdate=}}</ref> | ||
| Line 161: | Line 164: | ||
* There are no [[ECG]] findings associated with COVID-19-associated myelitis. | * There are no [[ECG]] findings associated with COVID-19-associated myelitis. | ||
* To view the electrocardiogram findings on COVID-19, [[COVID-19 electrocardiogram|click here]].<br /> | |||
===X-ray=== | ===X-ray=== | ||
* [[Chest X-ray]] may or may not show opacities in lungs depending on the degree of [[lung]] damage caused by COVID-19. | * [[Chest X-ray]] may or may not show opacities in lungs depending on the degree of [[lung]] damage caused by COVID-19. | ||
* To view the x-ray finidings on COVID-19, [[COVID-19 x ray|click here]].<br /> | |||
===Echocardiography or Ultrasound=== | ===Echocardiography or Ultrasound=== | ||
*There are no echocardiography findings associated with COVID-19-associated myelitis. | *There are no echocardiography findings associated with COVID-19-associated myelitis. | ||
*Abdominal [[ultrasound]] may show [[bladder distension]] due to [[urinary retention]]. | *Abdominal [[ultrasound]] may show [[bladder distension]] due to [[urinary retention]]. | ||
* To view the echocardiographic findings on COVID-19, [[COVID-19 echocardiography and ultrasound|click here]].<br /> | |||
===CT scan=== | ===CT scan=== | ||
| Line 187: | Line 193: | ||
* [[Oxygen]] [[inhalation]] [[treatment]] with high-flow [[nasal]] [[catheters]]. | * [[Oxygen]] [[inhalation]] [[treatment]] with high-flow [[nasal]] [[catheters]]. | ||
* [[Ganciclovir]]( 0.5g once daily) for 14 days | * [[Ganciclovir]] ( 0.5g once daily) for 14 days, [[Lopinavir]]/[[ritonavir]] (500mg twice daily) for 5 days. {{cite web |url=https://www.covid19treatmentguidelines.nih.gov/ |title=Coronavirus Disease 2019 (COVID-19) Treatment Guidelines |format= |work= |accessdate=}} | ||
* [[Moxifloxacin]] (400mg once daily) for 6 days.([[Treatment]] with [[arbidol]] and [[moxifloxacin]] could be helpful in reducing [[viral load]] and [[inflammation]] during [[SARS-CoV2]] [[infection]], especially for negatively regulating [[fatal]] [[inflammation]] in severe [[COVID-19]] patients)<ref name="YuSun2020">{{cite journal|last1=Yu|first1=Dongshan|last2=Sun|first2=Shuilin|last3=Li|first3=Yanhua|last4=Xi|first4=Wenna|last5=Jin|first5=Di|last6=Sun|first6=Ke|last7=Yu|first7=Rongyan|last8=Yao|first8=Xuebing|last9=Song|first9=Zhiying|last10=Yang|first10=Aoyu|last11=Luo|first11=Ruixia|last12=Zou|first12=Biaoshu|last13=Liu|first13=Yun|year=2020|doi=10.1101/2020.05.30.20117598}}</ref>. | |||
* [[Moxifloxacin]](400mg once daily) for 6 days.([[Treatment]] with [[arbidol]] and [[moxifloxacin]] could be helpful in reducing [[viral load]] and [[inflammation]] during [[SARS-CoV2]] [[infection]], especially for negatively regulating [[fatal]] [[inflammation]] in severe [[COVID-19]] patients)<ref name="YuSun2020">{{cite journal|last1=Yu|first1=Dongshan|last2=Sun|first2=Shuilin|last3=Li|first3=Yanhua|last4=Xi|first4=Wenna|last5=Jin|first5=Di|last6=Sun|first6=Ke|last7=Yu|first7=Rongyan|last8=Yao|first8=Xuebing|last9=Song|first9=Zhiying|last10=Yang|first10=Aoyu|last11=Luo|first11=Ruixia|last12=Zou|first12=Biaoshu|last13=Liu|first13=Yun|year=2020|doi=10.1101/2020.05.30.20117598}}</ref>. | * [[Glutathione]] (1.8g once daily) for 14 days. ([[Glutathione]] inhibits [[replication]] of various [[viruses]] at different stages of the [[viral]] [[life cycle]] and decreasing [[viral load]]. It also prevents the massive release of [[inflammatory]] cells into the [[lung]] “[[cytokine storm]]”)<ref name="De FloraGrassi1997">{{cite journal|last1=De Flora|first1=S.|last2=Grassi|first2=C.|last3=Carati|first3=L.|title=Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment|journal=European Respiratory Journal|volume=10|issue=7|year=1997|pages=1535–1541|issn=00000000|doi=10.1183/09031936.97.10071535}}</ref>. | ||
* [[Glutathione]](1.8g once daily) for 14 days. ([[Glutathione]] inhibits [[replication]] of various [[viruses]] at different stages of the [[viral]] [[life cycle]] and decreasing [[viral load]]. It also prevents the massive release of [[inflammatory]] cells into the [[lung]] “[[cytokine storm]]”)<ref name="De FloraGrassi1997">{{cite journal|last1=De Flora|first1=S.|last2=Grassi|first2=C.|last3=Carati|first3=L.|title=Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment|journal=European Respiratory Journal|volume=10|issue=7|year=1997|pages=1535–1541|issn=00000000|doi=10.1183/09031936.97.10071535}}</ref>. | * [[Dexamethasone]] (10mg once daily) for 10 days<ref name="SotocaRodríguez-Álvarez2020">{{cite journal|last1=Sotoca|first1=Javier|last2=Rodríguez-Álvarez|first2=Yensa|title=COVID-19-associated acute necrotizing myelitis|journal=Neurology - Neuroimmunology Neuroinflammation|volume=7|issue=5|year=2020|pages=e803|issn=2332-7812|doi=10.1212/NXI.0000000000000803}}</ref>. (NIH COVID-19 Treatment Guidelines Panel recommends using dexamethasone (at a dose of 6 mg per day for up to 10 days) in patients with COVID-19 who are mechanically ventilated and in patients with COVID-19 who require supplemental oxygen but who are not mechanically ventilated. And recommends against using dexamethasone in patients with COVID-19 who do not require supplemental oxygen. | ||
* [[Dexamethasone]] (10mg once daily) for 10 days<ref name="SotocaRodríguez-Álvarez2020">{{cite journal|last1=Sotoca|first1=Javier|last2=Rodríguez-Álvarez|first2=Yensa|title=COVID-19-associated acute necrotizing myelitis|journal=Neurology - Neuroimmunology Neuroinflammation|volume=7|issue=5|year=2020|pages=e803|issn=2332-7812|doi=10.1212/NXI.0000000000000803}}</ref>. | |||
* [[Human immunoglobulin]] (15g once daily) for 7 days. | * [[Human immunoglobulin]] (15g once daily) for 7 days. | ||
* [[Pantoprazole]] (80mg once daily) for 10 days. | |||
* [[Pantoprazole]](80mg once daily) for 10 days. | |||
* [[Mecobalamin]] (1000ug once daily) for 14days.<ref name="nairnarayanan">{{cite journal|last1=nair|first1=deepak t|last2=narayanan|first2=naveen|doi=10.35543/osf.io/p48fa}}</ref> ([[Vitamin B12]] may inhibit [[RNA-dependent-RNA polymerase]] activity of [[nsp12 protein]] from the [[COVID-19]] [[Virus]]). | * [[Mecobalamin]] (1000ug once daily) for 14days.<ref name="nairnarayanan">{{cite journal|last1=nair|first1=deepak t|last2=narayanan|first2=naveen|doi=10.35543/osf.io/p48fa}}</ref> ([[Vitamin B12]] may inhibit [[RNA-dependent-RNA polymerase]] activity of [[nsp12 protein]] from the [[COVID-19]] [[Virus]]). | ||
* Plasma exchange. | |||
* [[Foley catheter|Foley's catheter]] to relieve [[urinary retention]] | * [[Foley catheter|Foley's catheter]] to relieve [[urinary retention]] | ||
===Surgery=== | ===Surgery=== | ||
| Line 223: | Line 217: | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Up-To-Date]] | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 23:50, 12 December 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Musadiq Ali M.B.B.S.[2] Tayebah Chaudhry[3], Fahimeh Shojaei, M.D.
Synonyms and keywords:
Overview
In the current pandemic state, COVID-19 should be considered as a differential diagnosis in a patient presenting with acute myelitis. Acute Transverse Myelitis is a neurological condition characterized by inflammation and injury of the spinal cord. In a confirmed or newly diagnosed patient of COVID-19, it is thought to be either a direct consequence of viral infection or a sequalae of autoimmune-mediated response. COVID-19-associated myelitis is diagnosed based on the hallmark symptoms of acute myelitis and confirmed with changes on spinal MRI, after ruling out other possible etiologies of myelitis. The symptoms show marked improvement after treatment with steroids and plasma exchange.
Historical Perspective
- First case of acute myelitis as a COVID-19 complication was reported in February 2020 in Wuhan by Kang Zhao et al, in a 66 year old male patient. [1]
- The second case was reported in Boston by Sarma et al in a 28 year old female patient who developed acute myelitis 7 days after symptoms of upper respiratory tract infection. [2]
- As of now, only few case reports have been published in literature showing an association of COVID-19 with acute myelitis as a neurological complication.
Classification
- There is no established system for the classification of COVID-19-associated myelitis.
Pathophysiology
- The pathogenesis of the disease behind this manifestation is not fully understood yet.
- There is a strong evidence suggesting that COVID-19 virus uses angiotensin-converting enzyme2 (ACE2) as its receptor to interact with host cells.
- This evidence is based on the previous extensive SARS-CoV structural analyses that showed interactions between the SARS-CoV virus and ACE2 receptors and because of the marked sequence similarities between Covid-19 and the SARS-CoV virus it is hypothesized that COVID 19 virus pathogenesis is comparable.
- The ACE2 receptors are expressed on alveolar epithelial cells, intestinal enterocytes and arterial and venous endothelial cells.
- In the brain, only the vascular cells expressed ACE2 cell receptors, not the neurons; yet attachment of the virus to the vascular endothelium this could be a potential mechanism for dissemination of the virus into the brain by the blood circulation[3].
- It is also hypothesized that the virus can disseminate into the nervous system through the olfactory bulb in which sensory neurons connect the nasal cavity to the central nervous system by the axons, which terminate in the olfactory bulb and passes through the cribriform plate[4].
- Early‐phase COVID‐19‐affected patients may exhibit loss of smell and taste as a result of this [5].
- In advanced stages of the disease the neurological signs and symptoms observed with COVID‐19 could also be due to the effects of hypoxia, respiratory, and metabolic acidosis[6].
Causes
Apart from COVID-19 other causes of viral myelitis include[7]:
- Herpes viruses, including the one that causes shingles and chickenpox (zoster)
- Cytomegalovirus
- Epstein-Barr
- HIV
- Enteroviruses such as poliovirus and coxsackievirus
- West Nile
- Echovirus
- Zika
- Influenza
- Hepatitis B
- Mumps, measles and rubella
Other causes of myelitis are:
- Bacterial myelitis
- Fungal myelitis
- Parasitic myelitis
- Multiple Sclerosis
- Transverse Myelitis
- Autoimmune disorders like SLE and Sjogren’s Syndrome
- Sarcoidosis
- Vaccinations
Differentiating COVID-19-associated myelitis from other Diseases
- For further information about the differential diagnosis, click here.
- To view the differential diagnosis of COVID-19, click here.
Epidemiology and Demographics
- As of now, the incidence of acute myelitis associated with Covid-19 infection in unknown. [8][9]
- To view epidemiology and demographics for COVID-19, click here.
Risk Factors
- There are no established risk factors for COVID-19-associated myelitis. However, since this condition is a direct consequence of infection by the novel coronavirus, risk factors for COVID-19 should be considered.
- To view the risk factors of COVID-19, click here.
Screening
- Screening for COVID-19-associated myelitis is not currently done.
- To view screening for COVID-19, click here.
Natural History, Complications, and Prognosis
Natural History
- Myelitis associated with COVID-19 is an acute condition. The first case of COVID-19 associated myelitis developed the symptoms 5 days after the onset of fever. [1]
- The second case developed symptoms of myelitis 7 days after the upper respiratory symptoms. [2]
Complications
- Lack of prompt recognition and management may result in lasting neurological complications (such as residual loss of sensation in lower extremities) after novel corona virus infection. [2]
Prognosis
- Exact prognosis of COVID-19-associated myelitis is not known.
- Marked improvement in symptoms is seen with steroids and plasma exchange.
Diagnosis
Diagnostic Study of Choice
- Diagnosis of COVID-19-associated myelitis is based on the hallmark symptoms of acute myelitis in a known case of COVID-19 or a positive PCR nasal swab for COVID-19 in a new patient. And classic contrast-enhancing lesions on MRI spine.
- Hallmark symptoms of acute myelitis include bilateral symmetric weakness and sensory changes in extremities, urinary retention and lower back pain.
- Absence of visual symptoms such as eye pain or vision loss ( classically seen in Multiple Sclerosis or Neuromyelitis optica), negative immunoglobulin G auto-antibodies or oligoclonal bands, negative anti-nuclear antibody (ANA) test (very sensitive test for autoimmune diseases such as lupus), absence of other system involvement (such as skin rash, nodules, cardiac arrhythmias or arthritis seen in lupus or sarcoidosis) rule out other possible etiologies. [8]
History and Symptoms
Common symptoms
- Urinary retention [8]
- Lower back pain [2]
- Weakness in lower extremities [8]
Less common symptoms
- Paresthesias in lower extremities with possible ascension to upper extremities [2]
- Numbness in lower extremities with possible ascension to upper extremities[2]
- Numbness in tip of tongue [2]
Physical Examination
Vitals:
Abnormal vitals can be seen due to COVID-19 association. These include:
- Decreased O2 saturation
- Tachycardia
- Tachypnea
Abdominal exam:
- Palpable distended bladder
Neurological exam:
Neurological findings are symmetric and more severe in lower extremities. [1] [2] [8]
- Wide based gait
- Decreased muscle strength
- Decreased sensation
- Decreased proprioception
- Hyporeflexia
- Paresthesias
- Positive Lhermitte's sign
- Positive Babinski's sign bilaterally.
Laboratory Findings
Nasal swab:
Other Viral Screening:
- Viral PCR screening including Adenovirus, Herpes Simplex Virus (Type 1&2), Epstein Barr Virus, Cytomegalovirus, Human Immunodeficiency Virus (HIV) will yield negative results.
- Viral serology for Influenza Virus A and B, Parainfluenza 1-4, Respiratory Syncytial virus, Enterovirus and Rhinovirus with negative results.
- Negative antibody results for bacteria such as Chlamydia Pneumoniae, Bordetella Pertussis, Mycoplasma Pneumoniae and Borrelia.
MRI spine:
- MRI findings consistent with Acute Transverse Myelitis (involving more than three spinal cord segments) are seen. This includes widespread elongated signal changes throughout the gray matter of spinal cord, with no disc pathology or spinal canal narrowing. [2]
Urinary retention:
- Foley catheter insertion will show and relieve retained urine.
Lumbar Puncture (LP):
- CSF analysis may show lymphocytic pleocytosis and elevated protein level. [10]
To view the laboratory findings on COVID-19, click here
Electrocardiogram
- There are no ECG findings associated with COVID-19-associated myelitis.
- To view the electrocardiogram findings on COVID-19, click here.
X-ray
- Chest X-ray may or may not show opacities in lungs depending on the degree of lung damage caused by COVID-19.
- To view the x-ray finidings on COVID-19, click here.
Echocardiography or Ultrasound
- There are no echocardiography findings associated with COVID-19-associated myelitis.
- Abdominal ultrasound may show bladder distension due to urinary retention.
- To view the echocardiographic findings on COVID-19, click here.
CT scan
- CT scan exclude other causes that can cause myelitis.
- To view the CT scan findings on COVID-19, click here.
MRI
- MRI may be used to exclude other causes.
- MRI findings consistent with Acute Transverse Myelitis (involving more than three spinal cord segments) are seen.
- This includes widespread elongated signal changes throughout the gray matter of spinal cord, with no disc pathology or spinal canal narrowing.
- T2-weighted fast spin-echo and short-tau inversion recovery (STIR) are the best sequences to view the spinal cord lesions[11].
- To view other imaging findings on COVID-19, click here.
Treatment
Medical Therapy
- Oxygen inhalation treatment with high-flow nasal catheters.
- Ganciclovir ( 0.5g once daily) for 14 days, Lopinavir/ritonavir (500mg twice daily) for 5 days. "Coronavirus Disease 2019 (COVID-19) Treatment Guidelines".
- Moxifloxacin (400mg once daily) for 6 days.(Treatment with arbidol and moxifloxacin could be helpful in reducing viral load and inflammation during SARS-CoV2 infection, especially for negatively regulating fatal inflammation in severe COVID-19 patients)[12].
- Glutathione (1.8g once daily) for 14 days. (Glutathione inhibits replication of various viruses at different stages of the viral life cycle and decreasing viral load. It also prevents the massive release of inflammatory cells into the lung “cytokine storm”)[13].
- Dexamethasone (10mg once daily) for 10 days[14]. (NIH COVID-19 Treatment Guidelines Panel recommends using dexamethasone (at a dose of 6 mg per day for up to 10 days) in patients with COVID-19 who are mechanically ventilated and in patients with COVID-19 who require supplemental oxygen but who are not mechanically ventilated. And recommends against using dexamethasone in patients with COVID-19 who do not require supplemental oxygen.
- Human immunoglobulin (15g once daily) for 7 days.
- Pantoprazole (80mg once daily) for 10 days.
- Mecobalamin (1000ug once daily) for 14days.[15] (Vitamin B12 may inhibit RNA-dependent-RNA polymerase activity of nsp12 protein from the COVID-19 Virus).
- Plasma exchange.
- Foley's catheter to relieve urinary retention
Surgery
- Surgical intervention is not recommended for the management of COVID-19-associated myelitis.
Primary Prevention
- Effective measures for the primary prevention of COVID-19-associated myelitis are the same as of COVID-19.
Secondary Prevention
- Effective measures for the secondary prevention of COVID-19-associated myelitis are the same as of COVID-19.
References
- ↑ 1.0 1.1 1.2 "www.medrxiv.org" (PDF).
- ↑ Manji H, Carr AS, Brownlee WJ, Lunn MP (2020). "Neurology in the time of COVID-19". J Neurol Neurosurg Psychiatry. 91 (6): 568–570. doi:10.1136/jnnp-2020-323414. PMID 32312872 Check
|pmid=value (help). - ↑ Wan Y, Shang J, Graham R, Baric RS, Li F (2020). "Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus". J Virol. 94 (7). doi:10.1128/JVI.00127-20. PMC 7081895 Check
|pmc=value (help). PMID 31996437. - ↑ Baig AM (2020). "Neurological manifestations in COVID-19 caused by SARS-CoV-2". CNS Neurosci Ther. 26 (5): 499–501. doi:10.1111/cns.13372. PMC 7163592 Check
|pmc=value (help). PMID 32266761 Check|pmid=value (help). - ↑ Pastor Bandeira, Isabelle; Machado Schlindwein, Marco Antônio; Breis, Leticia Caroline; Schatzmann Peron, Jean Pierre; Magno Gonçalves, Marcus Vinicius (2020). doi:10.20944/preprints202004.0304.v1. Missing or empty
|title=(help) - ↑ Pekcevik Y, Mitchell CH, Mealy MA, Orman G, Lee IH, Newsome SD; et al. (2016). "Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging". Mult Scler. 22 (3): 302–11. doi:10.1177/1352458515591069. PMC 4797654. PMID 26209588.
- ↑ 8.0 8.1 8.2 8.3 8.4 8.5 AlKetbi, Reem; AlNuaimi, Dana; AlMulla, Muna; AlTalai, Nouf; Samir, Mohammed; Kumar, Navin (2020). "Acute Myelitis as a Neurological Complication ofCovid-19:A Case Report and MRI Findings". Radiology Case Reports. doi:10.1016/j.radcr.2020.06.001. ISSN 1930-0433.
- ↑ Munz M, Wessendorf S, Koretsis G, Tewald F, Baegi R, Krämer S; et al. (2020). "Acute transverse myelitis after COVID-19 pneumonia". J Neurol. doi:10.1007/s00415-020-09934-w. PMC 7250275 Check
|pmc=value (help). PMID 32458198 Check|pmid=value (help). - ↑ "Acute transverse myelitis after COVID-19 pneumonia".
- ↑ Scotti G, Gerevini S (2001). "Diagnosis and differential diagnosis of acute transverse myelopathy. The role of neuroradiological investigations and review of the literature". Neurol Sci. 22 Suppl 2: S69–73. doi:10.1007/s100720100038. PMID 11794482.
- ↑ Yu, Dongshan; Sun, Shuilin; Li, Yanhua; Xi, Wenna; Jin, Di; Sun, Ke; Yu, Rongyan; Yao, Xuebing; Song, Zhiying; Yang, Aoyu; Luo, Ruixia; Zou, Biaoshu; Liu, Yun (2020). doi:10.1101/2020.05.30.20117598. Missing or empty
|title=(help) - ↑ De Flora, S.; Grassi, C.; Carati, L. (1997). "Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment". European Respiratory Journal. 10 (7): 1535–1541. doi:10.1183/09031936.97.10071535. ISSN 0000-0000.
- ↑ Sotoca, Javier; Rodríguez-Álvarez, Yensa (2020). "COVID-19-associated acute necrotizing myelitis". Neurology - Neuroimmunology Neuroinflammation. 7 (5): e803. doi:10.1212/NXI.0000000000000803. ISSN 2332-7812.
- ↑ nair, deepak t; narayanan, naveen. doi:10.35543/osf.io/p48fa. Missing or empty
|title=(help)